Randomized crossover antiemetic study in cisplatin-treated patients - Comparison between high-dose IV metoclorpramide and high-dose IV dexamethasone

Sergio Frustaci, Enore Grattoni, Salvatore Tumolo, Diana Crivellari, Franco Figoli, Enzo Galligioni, Andrea Veronesi, Umberto Tirelli, Eligio Grigoletto

Research output: Contribution to journalArticle

Abstract

This prospective, randomized, nonblind study comparing the antiemetic effectiveness of high-dose IV metoclopramide and high-dose IV dexamthasone was performed in 78 advanced cancer patients. Chemotherapeutic treatment consisted in cisplatin at a high-dose (120 mg/m2) (HD-CDDP) and at a low-dose (LD-CDDP), either alone (60 mg/m2) or in combination with other chemotherapeutic agents (50 mg/m2). The evaluation of the effectiveness of antiemetic therapy was based on three parameters: prevention of vomiting ("major protection"), number of emetic episodes, and subjective preference. Out of 78 study patients, 67 were evaluable. Overall, metoclopramide proved to be statistically superior to dexamethasone in preventing vomiting (P

Original languageEnglish
Pages (from-to)75-79
Number of pages5
JournalCancer Chemotherapy and Pharmacology
Volume17
Issue number1
DOIs
Publication statusPublished - May 1986

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Randomized crossover antiemetic study in cisplatin-treated patients - Comparison between high-dose IV metoclorpramide and high-dose IV dexamethasone'. Together they form a unique fingerprint.

  • Cite this

    Frustaci, S., Grattoni, E., Tumolo, S., Crivellari, D., Figoli, F., Galligioni, E., Veronesi, A., Tirelli, U., & Grigoletto, E. (1986). Randomized crossover antiemetic study in cisplatin-treated patients - Comparison between high-dose IV metoclorpramide and high-dose IV dexamethasone. Cancer Chemotherapy and Pharmacology, 17(1), 75-79. https://doi.org/10.1007/BF00299870